The utility of adrenal and ovarian venous sampling in a progesterone-producing adrenal tumor and review of the literature

Lian Duan1 · Yingying Yang1 · Yu Gu2 · Xiaobo Zhang3 · Quanzong Mao4 · Boju Pan5 · Chengyan Deng6 · Hui Pan1 · Huijuan Zhu1

Received: 8 December 2018 / Accepted: 4 July 2019 / Published online: 27 August 2019 © The Author(s) 2019

Abstract
Purpose A clinical case presenting secondary amenorrhea accompanied by an adrenal adenoma and hyperprogesteronemia is described in this study.
Methods Selective catheterization and sampling of adrenal and ovarian veins were performed.
Results The source of hyperprogesteronemia was located in the right adrenal gland. A progesterone-producing tumor in the right adrenal gland was diagnosed and removed. Twenty-six days after tumor resection, menstruation occurred.
Conclusions Progesterone-producing tumors should be considered with the presence of an adrenal mass and hyperprogesteronemia. Combined adrenal and ovarian venous sampling may help to identify the source of progesterone secretion.

Keywords Amenorrhea · Progesterone-producing tumor · Combined adrenal and ovarian venous sampling

Introduction
Progesterone-producing tumors are extremely rare and easily overlooked in patients with hyperprogesteronemia. To our knowledge, there are only three published reports of adrenal progesterone-producing tumors. We encountered a case that exhibited secondary amenorrhea, elevated serum progesterone levels, and an adrenal tumor suspected to be producing progesterone and related adrenal steroid hormones. We diagnosed the patient’s condition with the use of combined adrenal and ovarian venous sampling. After resection of the adrenal tumor, serum progesterone concentrations soon normalized, and the patient became pregnant. This study is the first to use combined adrenal and ovarian venous sampling to confirm the source of hyperprogesteronemia.

Methods
Hormonal measurement
Serum or plasma levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), progesterone (P), estradiol (E2), testosterone (T), β-HCG, prolactin (PRL), dehydroepiandrosterone sulfate (DHEAs), cortisol (F), adrenocorticotropic hormone (ACTH), and urinary free
cortisol (UFC) were measured via chemiluminescence immunoassay. Plasma 17α-hydroxyprogesterone (17 α-OHP), aldosterone (ALD), renin activity (RA), and angiotensin (AT) were measured by radioimmunoassay. Plasma and urinary adrenaline, noradrenaline and dopamine were measured using high performance liquid chromatography. Immunohistological analysis of the progesterone was performed using an anti-progesterone antibody (GeneTex, Progesterone antibody, 9B4, 1/50) according to the instructions of the manufacturer. All above procedures were performed at the department of laboratory of Peking Union Medical College Hospital (Beijing, China).

**Combined adrenal and ovarian venous sampling**

Combined adrenal and ovarian venous sampling was performed by two experienced interventional radiologists. The patient was placed in the supine position and 5-F vascular catheter was accessed via the right femoral vein. Cobra catheter was then advanced into inferior vena cava and right adrenal vein and Simmons catheter was placed into the left ovarian vein under fluoroscopic guidance, respectively. Cobra catheter was placed into the left ovarian vein after. Five milliliters of venous blood were taken from each site simultaneously for P, 17 α-OHP, E₂, F, ALD, T, PRA, and a DHEAS assay. The E₂ ratio were taken from each site simultaneously for P, 17 α-OHP, 5 mg of prednisone acetate per day and E₂, 5 mg as dydrogesterone replacement were prescribed. However, menstruation still did not occur. The patient was then admitted to the Department of Endocrinology, where a medium-dose (3 mg) dexamethasone suppression test, which has been validated by Zhaolin Lu et al. [1], revealed her plasma progesterone, 17 α-OHP and cortisol were not suppressed whereas her ACTH was suppressed under 5 pg/ml (Table 1). A pelvic ultrasound showed that the patient had a normal uterus and normal ovaries with several follicles. Subsequent computed tomography (CT) of the adrenal glands revealed a 2.8 cm mass with inhomogeneous enhancement in the right adrenal gland. Combined adrenal and ovarian venous sampling was performed. The sampling indicated overproduction of progesterone, 17 α-OHP and cortisol in the right adrenal gland compared to the left gland (Fig. 1 and Table 1). Informed consent was obtained from the patient included in the study.

**Results**

The patient underwent laparoscopic resection of the right adrenal tumor, which was suspected of producing the excess progesterone, 17 α-OHP and cortisol (Table 1). A well-encapsulated tumor measuring 2.8 cm × 3.0 cm was removed (Fig. 1E). Unexpectedly, the cut surface of the tumor was an abnormally deep shade of red unique from other kinds of adrenocortical adenoma. The pathology was reviewed by an experienced endocrine pathologist and suggested adrenocortical adenoma. Histologically, the tumor cells were arranged in a nesting and trabecular pattern with eosinophilic cytoplasm and obvious nucleoli. The Weiss score was 2, with a nuclear grade between grade II and III; Only 1% of cells expressed Ki-67. Additionally, <25% of cells were clear, failing to meet the criteria for adrenocortical carcinoma [2]. With adrenocortical adenoma as a negative control, anti-progesterone antibodies detected progesterone immunoreactivity in the tumor cells (Fig. 2). Progesterone and 17 α-OHP levels normalized immediately after resection of the adrenal tumor (Table 1). The patient’s menstruation reoccurred 26 days after resection, and she was pregnant 3 months post surgery.

**Discussion**

**Differential diagnosis of amenorrhea**

In the presented case, the patient’s menstruation had stopped for more than 6 months despite experiencing prior menstruation. Therefore, secondary amenorrhea, which is often caused by pregnancy, hyperthyroidism, hypothalamic
dysfunction, pituitary, or ovarian dysfunction, was considered. The patient’s levels of thyroid hormone, PRL, and β-HCG were within normal ranges, as were her plasma ALD and androgen concentrations. However, elevated plasma progesterone and 17α-OHP concentrations were found without suppression of LH and FSH. Progesterone is produced by the adrenal glands and by the corpus luteum in the ovaries after ovulation is triggered by LH, but the patient’s serum progesterone levels did not return to normal after the luteal phase. Additionally, ovarian ultrasonography and abdominal CT did not show any abnormal ovarian growths. Thus, elevated progesterone levels of an adrenal

### Table 1: Preoperative and postoperative levels of serum and urine steroid hormone concentrations

| Plasma hormone | Pre   | Post<sup>a</sup> | Plasma hormone | Pre   | Post | Urine hormone | Pre   | Post |
|----------------|-------|------------------|----------------|-------|------|---------------|-------|------|
| ACTH           | 23.90 | 51.20            | PRL            | 17.58 | –    | 24 h UFC (µg/24 h) | 63.20 | 51.60 |
| F (8:00 a.m.)  | 9.79  | 5.34             | DHEA           | 59.70 | –    | 24 h UNE     | 36.49 | –    |
| F (10:00 a.m.) | 6.14↑ | –                | PRA            | 0.83  | –    | 24 h UE      | 5.45  | –    |
| LH             | 9.29  | 7.45             | AT-II          | 74.43 | –    | 24 h UDA     | 275.19| –    |
| FSH            | 10.41 | 9.99             | ALD            | 16.20 | –    |              |       |      |
| E2             | 15.00 | 13.61            | TSH            | 2.48  | –    |              |       |      |
| P              | 10.75↑| 0.25             | FT4            | 1.19  | –    |              |       |      |
| 17α-OHP        | 19.16↑| 0.51             | FT3            | 2.92  | –    |              |       |      |
| β-HCG          | 0.40  | –                |                |       |      |              |       |      |

| DST (3 mg)     | ACTH (pg/ml) | F (µg/dl) | P (ng/ml) | 17α-OHP (ng/ml) | T (ng/ml) | DHEAS (µg/dl) |
|----------------|--------------|-----------|-----------|-----------------|-----------|---------------|
| Basal values   | 18.40        | 8.84      | 8.92      | 15.33           | 0.32      | 20.1          |
| 0.75 mg × 4 Day 2 | <5.00       | 8.24↑     | 13.02     | 18.67↑          | 0.22      | 20.4          |

### AVS + OVS

| Plasma hormone | Baseline | Follicular phase | Ovulation | Luteal phase | Menopause |
|----------------|----------|-----------------|-----------|--------------|-----------|
| ACTH           | 6.40     | 8.18            | 5.23      | 6.13         | 8.87      | 70.84↑       |
| PRA            | 8.60     | 14.42           | 9.17      | 10.07        | 7.99      | 641.70↑      |
| 17α-OHP        | 14.92    | 29.20           | 16.26     | 15.89        | 17.53     | 85.65↑       |
| E2             | 62.09    | 69.34           | 704.61    | 1561.68      | 63.03     | 48.17        |
| T              | <0.10    | 0.18            | 0.33      | 1.48         | 0.15      | 1.02         |
| DHEAS          | 13.50    | 13.70           | 13.2      | 12.8         | 14.10     | 16.70        |
| PRA            | 0.13     | 0.24            | –         | –            | 0.01      | 0.21         |
| ALD            | 8.91     | 9.58            | –         | –            | 21.26     | 32.34        |

### Normal range:

- FSH (IU/L): <10.00 – 30.34 IU/L
- LH (IU/L): 2.12 – 10.89 IU/L
- E2 (pg/ml): 27 – 122 pg/ml
- P (ng/ml): 0.38 – 2.28 ng/ml
- 17α-OHP (ng/ml): 0.1 – 0.8 ng/ml

Normal range: T 0.1 – 0.75 ng/ml, DHEAS 23 – 266 µg/dl, ACTH 0 – 46 pg/ml, F (8:00 a.m.) 4.0 – 22.3 µg/dl, F (10:00 a.m.) < 1.8 µg/dl, β-HCG 0 – 10 IU/L, PRL < 30 ng/ml, DHEA 23 – 266 µg/dl, PRA 0.93 – 6.56 ng/ml, AT-II 25.3 – 145.3 pg/ml, ALD 6.5 – 29.6 ng/dl, TSH 0.38 – 3.84 µU/ml, FT4 0.81 – 1.89 ng/dl, FT3 1.8 – 4.1 pg/ml, 24 h UFC 12.3 – 103.5 µg/24 h, 24 h UNE 16.69 – 40.65 µg/24 h, 24 h UE 1.74 – 6.42 µg/24 h, 24 h UDA 120.93 – 330.59 µg/24 h

DHEAs dehydroisoandrosterone sulfate, PRA plasma renin activity, ALD aldosterone, AT-II angiotensin, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol, P progesterone, TSH thyroid-stimulating hormone, FT3 free triiodothyronine, FT4 free thyroxine, UFC urinary free cortisol, UNE urinary norepinephrine, UE urinary epinephrine, UDA urinary dopamine, DOC deoxycorticosterone, DST dexamethasone suppression test, AVS adrenal venous sampling, OVS ovarian venous sampling

<sup>a</sup>Post: 3 days after surgery
origin were suspected. High levels of progesterone and 17α-OHP are a potential consequence of CAH by 21-hydroxylase or 17-hydroxylase deficiency [3, 4]. CAH was subsequently excluded due to the failure of a medium dose of dexamethasone as well as glucocorticoid administration to normalize hormone levels. With the presence of a mass in the right adrenal gland, the possibility that progesterone, 17α-OHP and cortisol were autonomously secreted by the adrenal tumor was considered. Since the patient exhibited a favorable clinical outcome to tumor resection, she was
diagnosed with a progesterone and related steroid-producing adrenal tumor. It is possible that the patient failed to have artificial menses after she was prescribed estrogen and progesterone due to the endometrium’s poor response to estrogen in the presence of high concentrations of progesterone. However, the mechanism of non-suppressed plasma LH and FSH at baseline remained unclear. A previous study reported that the increased levels of serum progesterone of adrenal origin may cause an increase in LH concentrations [5]. Though the patient’s cortisol levels were not suppressed by the dexamethasone test and she did not present with any features of hypercortisolism, suggesting that a diagnosis of subclinical Cushing’s disease cannot be excluded. We observed that ACTH was not suppressed by cortisol excess, and this discrepancy could indicate that the serum cortisol lacked enough biological activity to inhibit that HPA axis.

**Overview of previously reported cases of progesterone-producing adrenal tumors**

Progesterone-producing tumors are extremely rare. Previous studies have reported cases with primary amenorrhea revealing an occult progesterone-secreting ovarian Leydig cell tumor and granulosa cell tumors [6–8]. To our knowledge, only three other cases have reported adrenal tumors producing progesterone [9–11] (Table 2). In each previous case, all patients complained of amenorrhea as their first symptom and were found to have elevated progesterone and 17α-OHP levels. In one patient, serum DOC was significantly increased with coinciding presentation of hypertension and hypokalemia. Giant adrenal incidentalomas over 5 cm in diameter were present in all patients; the large size of the adrenomas may be because the presentation of early symptoms in progesterone-producing tumors is not typical. Pathological examination of the tumor tissue after adrenalectomy resulted in the diagnosis of one patient who had an adrenal tumor that measured 12 cm with adrenocortical carcinoma, while the other two cases were diagnosed as benign cortical adenomas. Compared with the previous cases, the maximal diameter of the tumor described in the current study was only 2.8 cm, and no malignant sign was shown by microscopic examination. Elevated adrenal steroid intermediates immediately normalized and menstruation started soon after tumor resection during follow-up.

**Selective catheterization of adrenal and ovarian veins**

Selective catheterization of adrenal and ovarian veins was performed to confirm the source of hyperprogesteronemia and determine whether the right adrenal lesion was...
functional or nonfunctional. This revealed an over 60-fold increase in progesterone production from the right adrenal gland compared with the left adrenal and bilateral ovarian veins. In addition, 17α-OHP and cortisol concentrations in the right adrenal gland were 5–7 times higher than those found in the peripheral veins, left adrenal gland, and ovarian veins. Adrenal vein sampling is a highly accurate method used to localize ALD-secreting adenomas. Catheterization of ovarian veins has been used to identify the source of progesterone [6] and selective adrenal venous sampling together with ovarian venous sampling have primarily been used in the localization of occult androgen-secreting ovarian tumors [12–15]. We have also reported the diagnosis of ovarian ACTH-independent ectopic Cushing syndrome with the help of combined ovarian and adrenal venous sampling [16]. The current study, in combination with previous evidence, suggests that selective adrenal and ovarian vein sampling and associated steroid assays may be considered when the source of progesterone and other adrenal intermediate hormones cannot be determined by imaging methods, especially in cases in which the adrenal or ovarian tumor size is not yet large enough to be removed. However, ovarian and adrenal venous catheterization and sampling should only be performed by experienced doctors in order to achieve diagnostic value [12].

Conclusions

In summary, progesterone-producing tumors are easily overlooked in the differential diagnosis of amenorrhea since they are very rare in routine clinical practice. However, diagnosis of progesterone-producing tumors should be considered with the presence of an adrenal mass; furthermore, ovarian and adrenal venous catheterization and sampling may be highly valuable in the diagnosis of patients presenting small adrenal tumors.

Funding The National Key Program of Clinical Science (WBYZ2011-873).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. H. Tao, Z. Lu, B. Zhang, Y. Wang, M. Sun, Screening nonclassical 21-hydroxylase deficiency in androgen excess women of Chinese Han nationality. Chin. J. Endocrinol. Metab. 21(5), 405–8 (2005)
2. S. Aubert, A. Wacrenier, X. Leroy, P. Devos, B. Carnaille, C. Proye, J.L. Wemeau, M. Lecomte-Houcke, E. Leteurtre, Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 26(12), 1612–1619 (2002)
3. R.L. Rosenfield, S. Bickel, A.K. Razdan, Amenorrhea related to progesterone excess in congenital adrenal hyperplasia. Obstet. Gynecol. 56(2), 208–215 (1980)
4. D.J. Holmes-Walker, G.S. Conway, J.W. Honour, G. Rumsby, H.S. Jacobs, Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. 43(3), 291–296 (1995)
5. T. Eldar-Geva, E.J. Margalioth, B. Brooks, N. Algur, E. Zylber-Haran, Y.Z. Diamant, The origin of serum progesterone during the follicular phase of menstrin-stimulated cycles. Hum. Reprod. 13(1), 9–14 (1998)
6. H. Bry-Gaillard, G. Meduri, F. Abirached, E. Constancis, S. Brailly, P. Chanson, J. Young, Primary amenorrhea revealing an occult progesterone-secreting ovarian tumor. Fertil. Steril. 90(4), 1198.e1191–1198.e1195 (2008). https://doi.org/10.1016/j.fertnstert.2007.11.064
7. S.L. Tracy, F.B. Askin, R.L. Reddick, B. Jackson, R.J. Kurman, Progesterone secreting sertoli cell tumor of the ovary. Gynecol. Oncol. 22(1), 85–96 (1985). https://doi.org/10.1016/0090-8258(85)90011-3
8. C.W. Lomax, H.V. May Jr., W.B. Panko, W.N. Thornton Jr., Progesterone production by an ovarian granulosa cell carcinoma. Obstet. Gynecol. 50(1 Suppl), 39s–40s (1977)
9. P. van Zonneveld, H.P. Koppeschaar, T.W. de Bruin, T.M. Vroom, M.A. Blankenstein, T.J. van Vroo unhoven, A patient with a progesterone-producing adrenal adenoma who presented with primary amenorrhea. Gynecol. Endocrinol. 9(3), 189–194 (1995)
10. Y. Takahashi, J. Ninomiya, J. Horiguchi, H. Shimizu, M. Sato, Y. Koibuchi, T. Yoshida, M. Yoshida, D. Takata, H. Odawara, T. Yokoe, Y. Iino, Y. Morishita, M. Mori, Primary amenorrhea accompanied by adrenal adenoma: start of menarche soon after tumor resection. Intern. Med. 41(11), 972–976 (2002)
11. M. Sone, H. Shibata, K. Homma, N. Tamura, J. Akahira, S. Hamada, M. Yahata, N. Fukui, H. Itoh, H. Sasan, K. Nakao, Close examination of steroidogenesis disorders in a DOC—and progesterone—producing adrenocortical carcinoma. Endocrine 35(1), 25–33 (2009). https://doi.org/10.1007/s12020-008-9123-5
12. G.A. Kalitsas, J.J. Mukherjee, B. Kola, A.M. Isidori, J.A. Hanson, J.E. Dacie, R. Reznek, J.P. Monson, A.B. Grossman, Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin. Endocrinol. 59(1), 34–43 (2003)
13. L.C. Hickman, L. Goodman, T. Falcone, Value of selective venous catheterization in the diagnosis of hyperandrogenism. Fertil. Steril. 108(6), 1085 (2017). https://doi.org/10.1016/j.fertnstert.2017.08.037
14. C. Dunne, J.C. Havelock, Malignant ovarian Sertoli-Leydig cell tumor localized with selective ovarian vein sampling. J. Minim. Invasive Gynecol. 19(6), 789–793 (2012). https://doi.org/10.1016/j.jmig.2012.08.006

15. C.J. Petersons, M.G. Burt, The utility of adrenal and ovarian venous sampling in the investigation of androgen-secreting tumours. Intern. Med. J. 41(1a), 69–70 (2011). https://doi.org/10.1111/j.1445-5994.2010.02375.x

16. C. Patel, M. Matson, The role of interventional venous sampling in localising neuroendocrine tumours. Curr. Opin. Endocrinol. Diabetes, Obes. 18(4), 269–277 (2011). https://doi.org/10.1097/MED.0b013e32834804c8